To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.
- Assay duration:Multiple steps
- Assay Type (ELISA with LOV):Direct
- Conjugate ELISA:HRP
- Format:Pre-coated
- Primary antibody reactivity:Human
- Target protein:Pituitary secretory protein I , CgA, SP-I, CHGA
- Description:Chromogranin A human ELISA
- Size:1 kit
- Sample Type:Plasma-EDTA, plasma-heparin, plasma-citrate, urine, saliva
- Detection Method:Colorimetric
- Shelf Life:See expiration date
- Detection Range:0.14 - 33.33 pmol/ml
- Storage Temperature:2…8 °C
- Sample Volume:25 µl
- Regulatory Status:RUO
- Cat. No.:101424-310
- Supplier no.:RSCYK070R
This EIA kit is used for quantitative determination of CgA-LI in human plasma and saliva samples.
- Calibration Range: 0.14–33.33 pmol/mL
- Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Saliva, Urine: 25 ul/well
The kit is characterized for sensitive quantification, high specificity and no influence with other components in samples. Summary - Chromogranin A (CgA) is an acidic secretory protein consisting of 439 amino acids in human. The protein is found in a wide variety of hormone and neurotransmitter storage vesicles, and it is known be co-stored and co-released with catecholamines from adrenal medulla and sympathetic neuronal vesicles during exocytosis. O’Conner and Bernstein have first reported radioimmunological measurement of CgA in human plasma under conditions of physiologic, pharmacologic and pathologic alteration of sympathoadrenal function. Accumulated data, thereafter, have confirmed high concentrations of plasma or serum CgA measured by radioimmunoassay (CgA-like immunoreactivity: CgA-LI) in patients with neuroendocrine and endocrine tumors, especially in those with pheochromocytoma, anterior pituitary tumors and rectal and prostatic carcinoma. On the other hand, Nakane et al. recently discovered that CgA-LI exists in saliva, the concentration of which elevates rapidly under psychosomatic stress even prior to the elevation of salivary cortisol level. Subsequently, Kanno et al. presented an evidence for autonomic control of submandibular CgA-LI secretion in the anaesthetized rat.
This EIA kit for determination of human CgA in sample is based on the competitive enzyme immunoassay using combination of highly specific antibody to human CgA (344-374) and biotin-avidin affinity system. The 96-wells plate is coated with goat anti rabbit IgG. Human CgA standard or samples, labeled antigen and specific antibody are added to the wells for competitive immunoreaction. After incubation and plate washing, HRP labeled streptoavidin (SA-HRP) are added to form HRP labeled streptoavidin-labeled antigen-specific antibody complex on the surface of the wells. Finally, HRP enzyme activity is determined by o-Phenylenediamine dihydrochloride (OPD) and the concentration of human CgA is calculated.